Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

aap: LOQTEQ® VA Distal Radius System has clinically proven and receives high level of market acceptance

aap Implantate AG
Posted on: 18 Oct 16
  • First polyaxial system in LOQTEQ® product family since one year successful in the market

The evaluation following the market launch one year ago shows that the LOQTEQ® VA Distal Radius System 2.5 from aap Implantate AG (" aap ") has clinically proven and enjoys a high level of market acceptance. Both the implant and the related instruments meet with a positive response by users and customers. The LOQTEQ® VA Distal Radius System 2.5 is the first product in the LOQTEQ® VA (VA = Variable Angle) product family, which are polyaxial implants that facilitate inserting angle-stable screws at different angles. Polyaxial implants are required for treating areas such as the hand that in surgery require both angle stability and flexibility in the insertion of screws.

The LOQTEQ® VA Distal Radius System 2.5 was developed for the treatment of fractures of the distal radius (radius close to the wrist) and the distal ulna (ulna close to the wrist). Radius fractures account for about a quarter of all fractures. To meet patients' growing demands, a fast, mobilization-stable treatment with a permanent retention of the repositioning result is required. The special combination of anatomically preformed and small, angle-stable plates in conjunction with freely selectable screw angles and user-friendly instruments fulfils all the requirements of modern fracture management.   After already granted FDA approval the polyaxial radius system has been in use in the USA since this year as well and receives an especially high acceptance there. A sterilizing and a sieve system were developed specially for the U.S. market. Overall the wide range of plates in a compact set and specially developed instruments such as the screwdriver, co-designed by users, meet with a positive response. As radius fractures belong to the most frequent fractures the system is a sales driver. aap will shortly be launching further polyaxial variants of different LOQTEQ® products for various anatomical areas in the market.    

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ® and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap 's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@ aap .de  

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: aap Implantate AG via GlobeNewswire

Last updated on: 19/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.